Diagnosis of Parkinson's disease (PD) is currently assessed by the clinical evaluation of extrapyramidal signs. The identification of specific biomarkers would be advisable, however most studies stop at the discovery phase, with no biomarkers reaching clinical exploitation. To this purpose, we developed an automated literature analysis procedure to retrieve all the background knowledge available in public databases. The bioinformatic platform allowed us to analyze more than 51000 scientific papers dealing with PD, containing information on 4121 proteins. Out of these, we could track back 35 PD-related proteins as present in at least two published 2-DE maps of human plasma.
Introduction
The identification of specific biomarkers for neurodegenerative disorders is one of the main goal of the current clinical research. Diagnosis of the second most common neurological disorder, Parkinson's disease (PD), is currently assessed by the clinical evaluation of extrapyramidal signs, such as tremor, rigidity and bradykinesia, when the degeneration of dopaminergic nigral neurons has raised over 70% [1] , [2] . The identification of peripheral PD biomarkers would be critical for the differential diagnosis between PD and other neurodegenerative diseases that share some clinical features with PD. Moreover, early diagnosis remains a primary aim, needed also for the assessment of disease-modifying drugs [3] , [4] , [5] . Eventually, biomarkers of disease progression would allow a better patients follow-up and an objective measurement in clinical trials [6] . Non-motor signs frequently precede the onset of typical PD motor dysfunctions but they lack the specificity to be informative for the clinician; on the other hand, instrumental investigations (polysomnograpy or functional imaging) are characterized by high costs and the use of radioactive tracers. For these reasons, a biochemical marker to be evaluated in the periphery would be highly preferred [3] , [4] , [5] .
Several PD biomarker candidates were discovered using unbiased proteomic approaches [4] , [7] . 2-DE is able to resolve thousands of spots simultaneously and can visualize protein processing and post-translational modifications [8] . For these reasons, it has been widely used in biomarker discovery studies. In regards to the tissue where to look for biomarkers, human plasma was broadly exploited because potentially informative about almost any disease state and very easy to obtain with little discomfort for patients. Moreover, plasma seems to be suitable for proteomic analyses to be applied A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 5 in the clinical practice [9] . Nevertheless, the proteomic investigation of human plasma, especially by 2-DE, has proved to be challenging, because of the very complex nature of the sample and the presence of few highly-abundant proteins [10] .
Meta-analysis of proteomics data may represent a valuable tool to extract information from datasets present in the literature, thus increasing the sample size with respect to a single proteomics study [11] . In particular, meta-analysis of 2-DE data available in the literature has proved to have a great potential to retrieve valuable information related to Parkinson's disease, which otherwise would remain hidden [12] .
Plenty of information is available online in public domain databases. However, these datasets need to be filtered in order to sensibly and specifically find proteins that are associated to PD as biomarkers [13] . Here again, meta-analysis of 2-DE experiments present in the scientific literature or in pertinent datasets can help to identify biologically relevant biomarkers by filtering out proteins involved in generic processes (e.g., cell-cycle control, signal transduction, and stress responses) [14] . Eventually, the data obtained from the analysis of the literature should be further validated in an independent manner in a cohort large enough to ensure statistical significance.
In this study, we developed a bioinformatic platform for the automatic analysis of 
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Methods

2-DE gel database and proteomic meta-analysis
In order to extract human plasma 2-DE images from the literature, we parsed PDF files of selected articles using the BFO Java library (http://bfo.com) as previously described [12] . Briefly, the 2-DE images extracted from proteomic papers were annotated for all the protein spots, according to identifications provided by the article authors, matching the symbols and labels on the gels to the information given in the tables or in the text of the paper. Spots were further associated to their pixel cartesian position and to pI and MW data. 
Subjects
Ninety subjects were enrolled by the Department of Neurology at the Aosta Regional Hospital, after approval by the local Institutional Review Board. All patients signed an informed consent before being recruited for the present study, according to the by matching with the database created as described in paragraph 2.1 were excised from gels and the corresponding proteins identified by LC-MS/MS fragmentation.
Statistical analysis
Spot volumes were normalized by the total volume of a subset of spots common to all gels. Spots that were missing in more than 25% of gels were not taken into account.
Missing spot values in less than 25% of gels were replaced by the mean value of the spot volume of the group or, if the mean was lower than the 98th percentile, by the minimum value observed in the group [15] . Relative volumes were analyzed by the non-parametric Wilcoxon test to find significant differences (p < 0.05) in patients with PD with respect to control subjects and in PD patients treated or not with dopamine agonists [16] , [17] .
The Pearson linear correlation coefficient r was evaluated according to Eq. 1, where
x is the independent variable (i.e., age, daily L-DOPA dose), y is the relative spot volume, x is the mean x value, y is the mean y value, xy is the x × y product, xy is the product of x and y mean values. Predictive models for the classification of PD patients with respect to control subjects were built by linear discriminant analysis (LDA) of the spots identified as described above [16] . In this case, missing values were set to half of the minimum value observed in the gel. A likelihood score was assigned to each subject by linear combination of relative spot volumes according to Eq. 2.
A simplified model was obtained by removing spots with lower discriminating weight (W), calculated according to Eq. 3,
is the absolute separation of the mean values of spot i in control subjects (CO) and PD. Predictive models have been tested with the leave-one-out method and their performance quantified by measuring the area under the receiver operating characteristic (ROC)
curve [16] .
Aggregative nesting of spots included in the predictive model was based on pairwise Pearson correlation (Eq. 1), where x and y are relative spot volumes.
The minimum number of subjects to be included in validation studies was calculated according to Eq. 4,
where σ CO and σ PD are standard deviations of relative spot volumes in CO and PD groups, N CO and N PD are numbers of subjects in the groups, and μ CO and μ PD are mean values of relative spot volumes in the groups [16] .
All procedures for data analysis and graphics were written in R, an open-source environment for statistical computing [18] and are available at http://dx.doi.org/10.1038/protex.2013.001.
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In-gel digestion, mass spectrometry and protein identification
Spots were manually excised and destained (50% ethanol), dehydrated with acetonitrile (Sigma-Aldrich) (2 × 100 µl, 20 min) and then dried at 37°C by vacuum centrifugation.
Protein spots were trypsin digested as already described [19] . 
Results
Meta-analysis reveals nine candidate PD biomarkers
First of all, as described in the methods section we have populated a database with 22 2-DE gel images of whole human plasma, extracted from proteomics papers or from the Swiss 2D page database (http://world-2dpage.expasy.org). The gel spots were annotated A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 11 as described in paragraph 2.1. Within the selected 22 images, we have assigned 927 different spots corresponding to a total of 188 independent proteins.
We filtered these proteins in order to consider only those having at least two citations in papers related to PD. To this aim, we used ProteinQuest (http://www.proteinquest.com), a web-based platform for the mining of Medline papers, which allows the identification of the co-occurrence of biological concepts (e.g., proteins, disease names, drugs). In particular, we used ProteinQuest to analyze the cooccurrence between PD-related terminology and the 188 proteins annotated in our 2-DE gel database. As a result, 84 of these proteins occurred in at least two papers related to PD. Among these proteins, we selected only proteins that were already defined as potential PD biomarkers (e.g., by ignoring proteins related to the pathogenesis) and
were detectable in 2-DE plasma gels (thus excluding proteins with low abundance). In this way, we identified 9 different proteins (haptoglobin (HP), transthyretin (TTR), apolipoprotein A-1 (APOA1), serum amyloid P component (SAP), apolipoprotein E (APOE), complement factor H (CFH), fibrinogen γ (FGG), thrombin (F2) and complement c3 (C3)) that satisfy all the requirements, i.e., to be a protein visible on a plasma 2-DE gel and at the same time to be known as a potential biomarker of PD. The nine potential biomarker proteins, split into 32 spots, were identified as suitable source for a diagnostic pattern and were considered for the subsequent analysis; the increase or decrease of protein concentration as expected from the analyzed literature is reported in Supplementary Table 1 .
Two-dimensional electrophoresis profiling of plasma proteins
To perform the biomarker validation analysis, we obtained plasma protein expression profiles from the enrolled groups by 2-DE. First, we performed technical replicates for 1A ). Moreover, we calculated the intra-group standard deviation of spot volumes to verify if they were normally or log-normally distributed. As commonly observed in biological variables, standard deviations of spot volumes after logarithmic transformation were constant in both groups (Fig. 1B) . For this reason, we decided to rely on the non-parametric Wilcoxon test [16] . Moreover, we compared pairs of 2-DE gels from different subjects by Pearson linear correlation and analyzed the distribution of fitting residuals to assess the correctness of a pairwise comparison. Supplementary   Fig. 1 shows the studentized residuals against ranked magnitudes (QQ) plots [18] . On this basis, a direct proportionality between gels from different subjects may be assumed.
Once tested the quality of 2-DE maps, we screened the profiles to identify proteins or protein modifications whose changes were linked to confounding factors such as 
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ACCEPTED MANUSCRIPT 13 26, 41, 45, 66, 89 and 105) were identified by LC-MS/MS (see Table 3 and Supplementary Table 2 for details on protein identification by mass spectrometry).
Validation of candidate biomarkers
First of all, we verified the presence of the nine candidate biomarkers identified as described in paragraph 3.1 among the proteins that showed Table 2 ).
On the contrary, serum amyloid P component, fibrinogen γ and thrombin were excluded from the diagnostic pattern because not confirmed by our experimental data.
Interestingly, FGG was excluded because the level of spots corresponding to this protein correlated with L-DOPA daily dose and age.
Eventually, dealing with a large cohort of subjects, we observed significant level changes in spots that were not included in the results of the meta-analysis procedure (Spots no. 34, 41, 44, 45, 46, 61, 62, 66, 105, 147 and 150), thus allowing us to enrich the list of biomarker candidates found in plasma by 2-DE (for spot-protein correspondence see Table 2 ).
Linear discriminant analysis of selected spot levels
We analyzed all spots (n = 25) showing significantly different levels in PD patients by LDA, so to select the spots with the higher weight. The 10 spots showing the worst contribution (weight < 0.07) were discarded. The remaining 15 spots were clustered by aggregative nesting to detect the extent of correlation among spots (Fig. 3A) . These spots were analyzed again by LDA. Likelihood scores (PD Score, obtained as a linear
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ACCEPTED MANUSCRIPT 14 combination of relative spot volumes) were significantly different in PD patients with respect to control subjects (Wilcoxon test, p < 10 -16 ) (Fig. 3B ). To effectively test the performance of the model, each subject was iteratively excluded from the training set and predicted on the basis of the other subjects. The "leave-one-out" cross-validation procedure of the model allowed us to obtain 83% sensitivity and 82% specificity.
Predictions obtained so far were used to build a ROC curve with an area under curve of 0.886 (Fig. 3C) .
To test the power of our analysis we evaluated the intra-group variance and the difference of mean values for each spot listed in Table 2 . The minimum number of subjects required for a significant verification is always lower than 45 with the only exception of spots 38, 44 and 117 (Supplementary Table 3 ). Supplementary Fig. 1 ). Eventually, our experimental design included a group of non-healthy control subjects in order to eliminate false candidate biomarkers linked to a general state of inflammation present in PD patients. Indeed, different pieces of evidence suggest a possible implication of inflammation in the degeneration of dopaminergic neurons [20] .
Discussion
Despite the precautions to avoid possible common biases of biomarkers discovery studies, our approach verified six out of nine candidate biomarkers, namely haptoglobin, transthyretin, apolipoprotein A-1, apolipoprotein E, complement factor H and complement c3. In particular, HP and CFH showed the highest significance.
HP is an acute phase protein synthesized by liver cells, which has been widely proposed as a PD biomarker [21] , [22] . HP probably plays a modulatory and protective role on autoimmune inflammation of the CNS [23] and on the integrity of the nigrostriatal dopaminergic system [24] . Therefore, its altered levels could mirror the
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ACCEPTED MANUSCRIPT 16 neurodegenerative process at the central level. Notwithstanding this, a single isoform of HP was excluded from the panel because of its correlation with the assumption of dopamine agonists. The advantage of 2-DE, in this case, is the possibility to analyze the different forms of the same protein separately. CFH is a cofactor in the inactivation of C3b by factor I and also increases the rate of dissociation of the C3bBb complex (C3 convertase) and the (C3b)NBB complex (C5 convertase) in the alternative complement pathway. Our results support the hypotheses of a dysregulation of the complement pathways in neurodegenerative disorders and in PD in particular [7] and are in agreement with a significant reduction in factor H levels observed in the CSF of PD patients [25] . A single fragment of C3 was found to change in our cohort, but we cannot exclude that other fragments beyond our limit of detection are effectively changing. In any case, the power analysis revealed that this spot is characterized by a high variability and that the number of subjects to be analyzed should be higher. Also TTR would require a higher number of subjects to be considered a real PD biomarker.
On the other hand, we were not able to confirm the validity of thrombin (F2), gamma fibrinogen (FGG) and serum amyloid P component (SAP). Thrombin exerts physiological and pathological functions in the central nervous system, and it has been documented that the level of thrombin increases in human brain of patients with
Parkinson's disease [26] , [27] . Nevertheless, the differences in concentration may not be detected at the peripheral level. Additionally, higher F2 levels have been associated to ischemic injury [28] , a finding that could reduce the significance of this candidate biomarker when control subjects include stroke patients as it is our case. SAP was not significantly different between patients and control subjects, probably because PD patients were compared with neurological control subjects, who might have altered
levels of acute phase proteins. Moreover, even if FGG was correlated to PD, we excluded it from the panel because of the correlation of its levels with the therapy assumed by PD patients. In verification studies, it is particularly important to eliminate confounding effects such as the pharmacological treatment, that intrinsically discriminate between patients and control subjects [17] .
Furthermore, the experimental validation procedure allowed us to identify a set of additional candidate biomarkers that were not present in the list of proteins to be validated in the present study. Some of them have been already associated to PD, however they were not identified by the automated literature search because they did not fulfill the stringency parameters imposed in the analysis process. For instance, apolipoprotein A-IV has been proposed as a plasma PD biomarker only once [22] .
Therefore, it was filtered out during the automated analysis of literature.
In other cases, we observed a significant variation in proteins whose change in association with PD was not reported previously or is controversial. For instance, we observed that α2-macroglobulin level was lower in plasma of PD patients with respect to neurological, non-neurodegenerative control subjects. This protein has been originally proposed as a PD marker [29] , but other studies contradict the original hypothesis [30] . As a matter of fact, like many other inflammatory markers, α2macroglobulin displays constant levels in PD patients with different motor and cognitive impairment [31] . This finding highlights again the importance of the choice of the appropriate control group.
Eventually, a linear discriminant analysis was applied to identify the set of 15 spots that performed at best in discriminating PD patients from control subjects. A hierarchical clustering of these spots showed a major contribution of HP isoforms, 
Conclusions
The present study shows a possible pipeline to validate candidate PD biomarkers.
Starting from a broad automated analysis of the literature, we selected few proposed biomarkers in plasma and verified them in a cohort of 90 subjects. Some of the candidates, that arose from the literature analysis, were confirmed. At the same time, we identified other proteins whose level was different between PD patients and control subjects. Putting all the results together, we performed a LDA and assigned a weight to each protein. In this way, we selected the 15 most relevant contributors to a PD predictive model. Taken altogether, these data suggest that an automated analysis of literature data provides a useful tool to biomarkers validation studies. Hierarchical clustering of spot intensities shows two outgroups. One of them groups together all HP isoforms, while the other includes all the other spots and is enriched in apolipoproteins (A). Panels B and C report prediction results by the "leave-one-out" cross-validation procedure in terms of PD likelihood score distribution in the two groups (B) and classification performance, represented by the ROC curve (C).
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